• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older.

作者信息

Surie Diya, Self Wesley H, Zhu Yuwei, Yuengling Katharine A, Johnson Cassandra A, Grijalva Carlos G, Dawood Fatimah S

机构信息

Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

JAMA. 2024 Oct 1;332(13):1105-1107. doi: 10.1001/jama.2024.15775.

DOI:10.1001/jama.2024.15775
PMID:39230920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11375516/
Abstract
摘要

相似文献

1
RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older.呼吸道合胞病毒疫苗对60岁及以上美国成年人住院治疗的有效性
JAMA. 2024 Oct 1;332(13):1105-1107. doi: 10.1001/jama.2024.15775.
2
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.呼吸道合胞病毒相关下呼吸道疾病的估计疫苗效力
JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832.
3
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.呼吸道合胞病毒（RSV）疫苗对美国 60 岁及以上成年人因 RSV 相关住院和急诊就诊的有效性，2023 年 10 月至 2024 年 3 月：一项阴性检测设计分析。
Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0.
4
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States.佐剂RSVPreF3疫苗在美国≥60岁成年人中的成本效益。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2432745. doi: 10.1080/21645515.2024.2432745. Epub 2024 Dec 9.
5
Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.AS01E 佐剂呼吸道合胞病毒融合前 F 蛋白疫苗在老年人中接种 1 剂后的免疫原性和安全性：一项 3 期试验。
J Infect Dis. 2024 Jul 25;230(1):e102-e110. doi: 10.1093/infdis/jiad546.
6
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan.在日本，为 60 岁及以上成年人接种含佐剂的融合前 F 蛋白疫苗（RSVPreF3 OA）的成本效益分析。
Expert Rev Vaccines. 2024 Jan-Dec;23(1):986-996. doi: 10.1080/14760584.2024.2410898. Epub 2024 Oct 30.
7
Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.60 岁及以上成年人接种呼吸道合胞病毒疫苗的成本效益。
Vaccine. 2024 Oct 24;42(24):126294. doi: 10.1016/j.vaccine.2024.126294. Epub 2024 Sep 5.
8
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.在一项3期临床研究中，一种基于改良安卡拉痘苗病毒载体的多价呼吸道合胞病毒（RSV）疫苗对老年人中由RSV引起的疾病显示出适度的保护作用。
Vaccine. 2024 Dec 2;42(26):126427. doi: 10.1016/j.vaccine.2024.126427. Epub 2024 Oct 25.
9
Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.基于融合前 F 蛋白的疫苗预防美国老年人呼吸道合胞病毒病的成本效益分析。
Clin Infect Dis. 2024 May 15;78(5):1328-1335. doi: 10.1093/cid/ciad658.
10
Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.模拟澳大利亚孕妇呼吸道合胞病毒（RSV）疫苗接种的流行病学影响。
Vaccine. 2024 Dec 2;42(26):126418. doi: 10.1016/j.vaccine.2024.126418. Epub 2024 Oct 17.

引用本文的文献

1
RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons.呼吸道合胞病毒疫苗在两个季节对60岁及以上美国成年人住院治疗的有效性
JAMA. 2025 Aug 30. doi: 10.1001/jama.2025.15896.
2
Respiratory syncytial virus infection in adult and paediatric patients admitted to intensive care in Australia: A nation-wide comparison with COVID-19.澳大利亚重症监护病房收治的成人和儿童患者的呼吸道合胞病毒感染：与新冠肺炎的全国性比较
Crit Care Resusc. 2025 Jun 27;27(2):100113. doi: 10.1016/j.ccrj.2025.100113. eCollection 2025 Jun.
3
Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older.60岁及以上日本成年人中一种二价呼吸道合胞病毒融合前疫苗的成本效益分析。
Infect Dis Ther. 2025 Jul 6. doi: 10.1007/s40121-025-01177-4.
4
Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis.尼塞韦单抗、呼吸道合胞病毒（RSV）母体疫苗和老年人RSV疫苗在现实世界中的应用：一项系统评价和荟萃分析。
EClinicalMedicine. 2025 Jun 3;84:103281. doi: 10.1016/j.eclinm.2025.103281. eCollection 2025 Jun.
5
Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older.呼吸道合胞病毒疫苗对60岁及以上美国成年人的有效性和安全性
JAMA Netw Open. 2025 May 1;8(5):e258322. doi: 10.1001/jamanetworkopen.2025.8322.
6
Recent advances in the prevention and treatment of respiratory syncytial virus disease.呼吸道合胞病毒疾病预防与治疗的最新进展
J Gen Virol. 2025 Apr;106(4). doi: 10.1099/jgv.0.002095.
7
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination.与呼吸道合胞病毒疫苗接种相关的患者及社区层面特征
JAMA Netw Open. 2025 Apr 1;8(4):e252841. doi: 10.1001/jamanetworkopen.2025.2841.
8
Vaccination Strategies in Respiratory Diseases: Recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS, and SItI.呼吸系统疾病的疫苗接种策略：来自AIPO-ITS/ETS、SIMIT、SIP/IRS和SItI的建议。
Respiration. 2025;104(8):556-574. doi: 10.1159/000544919. Epub 2025 Mar 9.
9
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines.呼吸道合胞病毒疫苗的研发、现状及尚存挑战
Vaccines (Basel). 2025 Jan 21;13(2):97. doi: 10.3390/vaccines13020097.
10
Update on Vaccination Recommendations for Adults with HIV.成人HIV感染者疫苗接种建议的最新情况
Curr HIV/AIDS Rep. 2025 Feb 20;22(1):17. doi: 10.1007/s11904-025-00731-6.